Trials / Not Yet Recruiting
Not Yet RecruitingNCT06900192
A Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis
A Multicenter Phase 1 Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis Using Orca-Q, an Engineered Donor Graft Derived From Mobilized Peripheral Blood
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Stanford University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
A study of alloHCT with Orca-Q for the treatment of primary progressive multiple sclerosis (MS).
Detailed description
This study will evaluate alloHCT with Orca-Q, an allogeneic hematopoietic graft isolated from a donor's hematopoietic cells for the treatment of primary progressive MS.
Conditions
- Primary Progressive Multiple Sclerosis
- Multiple Sclerosis
- Multiple Sclerosis, Primary Progressive
- Multiple Sclerosis, Secondary Progressive
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Orca-Q | Allogeneic (donor) stem cell graft |
| DRUG | myeloablative regimen | Myeloablative regimen of busulfan, fludarabine, and thiotepa. |
Timeline
- Start date
- 2025-03-01
- Primary completion
- 2029-08-01
- Completion
- 2029-08-01
- First posted
- 2025-03-28
- Last updated
- 2025-03-28
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06900192. Inclusion in this directory is not an endorsement.